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Cynthia Casson Morton2,*Good afternoon, and welcome to San Diego and the 64th
meeting of The American Society of Human Genetics
(ASHG). It’s my privilege to stand before you today as the
president of this society—truly an honor and a dream—a
dream that I hope some of you here in the audience might
dare to dream, because it is truly a dream worth dreaming.
Beginning with the first meeting I attended in 1979 in
Minneapolis, being a member of this society has been
one of the most treasured aspects of my career as a human
geneticist. I am very grateful to Walter Nance, chair of the
Department of Human Genetics at the Medical College
of Virginia during my tenure there as a graduate student,
for making this meeting an integral part of our graduate-
student trainee development as human geneticists. With
the exception of the international meeting held in
Washington in 1991, during which time I was in labor
and delivery at Brigham and Women’s Hospital in Boston,
it has been my special pleasure to be present at all of the
meetings since 1979. I have countless wonderful memories
of the meetings over those years—of the science and of the
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The Ameno different, and I will speculate that it might even exceed
your expectations! Many thanks go to all of those who
have worked tirelessly to make this 64th annual meeting
possible, especially to the ASHG staff and the members of
the program committee.
I’d like to offer a special welcome to all trainee mem-
bers who join us for this meeting; you are the future
of this organization that we so cherish. Trainee badges
have a special designation so that you will be able to
find each other throughout the meeting. Thank you for
being with us and for preparing for the roles you will
have in this society. Be sure to join us at the business
meeting, where you will hear reports of the society
committees.
Next, I’d like to extend a warm welcome to all of our
international attendees. Many of you have traveled great
distances and processed considerable paperwork to be
with us on these shores, and I thank you deeply for
your efforts because we strive to be a society of human
geneticists who appreciate the privileges and challenges
of the work before all of us as a global community.
Despite the daily sadness from the news of the many
current struggles of humankind, in this hall we have
the freedom to join together on common ground for a
common glory—we share the language of science, we
treasure the diversity of our cultures, and we have hope
and responsibility for our discipline to bring improved
health to future generations of the residents of planet
Earth. As human geneticists, this is ‘‘the time of our
lives,’’ and the phrase, ‘‘To whom much has been given,
much is expected,’’ echoes through my thoughts in so
many dimensions.
On a personal note, writing this presidential address
has been a journey for me, and I imagine that sentiment
is shared by many past presidents, who have frequently
asked me when I have been in their presence, ‘‘How’s
the address coming’’? I found myself replying to each
of them, who happened to be men, that for me, it was
not just about the address, but as a woman, it was also
about the dress! As I labored over this task, I realized
that the requirements for this address could include be-
ing entertaining, uplifting, visionary, and personal—
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about ‘‘the time of my life’’ as a human and medical
geneticist.
Communication and Collaboration for a Common
Glory
My remarks today will be centered in part around a theme
of communication and collaboration.for a common
glory. The phrase ‘‘common glory’’ is a special one to me
as a graduate of the College of William and Mary in
Virginia. On campus, an outdoor theater backing up on
Lake Matoaka was the site for 30 years of a Paul Green
symphonic drama entitled The Common Glory. Produced
by the Jamestown Corporation, it tells the story of the
American Revolution. As I think ahead for our discipline
and our society, I have great excitement and hope for our
common glory.
Opportunities of the Omics Era and Precision
Medicine
There can be no doubt that we are living at an unprece-
dented time in the history of biology and medicine.1 The
exploding access to big biological data, and lots of it,
from individuals with clinical phenotypes and to their
disease (or health) outcomes will inform our knowledge.
Insights into frightening infectious diseases, such as the
current Ebola epidemic, are being made through genomic
approaches that make it possible to assess how the virus
is evolving to improve current diagnostic tests and to guide
work on vaccines and treatments. Individualized therapies
and new targets for drug development are opportunities
to improve medical management. Ever enlarging data
sets about our biology will be the drivers of the future of
medicine.
Part 1: Mapping the Human Genome
I fondly recall presentations by Victor McKusick about our
role as cartographers—our task was to construct the map of
the human genome—and for decades he was certainly the
master curator of that map. I owe a special thanks to Victor
with regard to my personal involvement in gene mapping.
It was during the 1981 Annual Short Course on Medical
and Experimental Mammalian Genetics (by the way,
this has been a destination stop for human geneticists for
55 years now) that I met a postdoc of Philip Leder’s, Lanny
Kirsch, while assisting in an afternoon session where
karyotyping using photos, scissors, and tape was being
held. That conversation led to my learning chromosomal
in situ hybridization and the mapping within the next
year of the immunoglobulin heavy chain locus to 14q32
and ofMYC to 8q24—and it ‘‘did not escape our attention’’
that there was a relationship with the t(8;14) in Burkitt
lymphoma.2
Many of you will remember the fun of the days of the
mapping meetings—days when we placed genes one by
one on chromosomes, when we estimated the human
genome to be composed of 100,000 genes, and when
computer security was so unsophisticated that the editors348 The American Journal of Human Genetics 96, 347–351, March 5of one chromosome committee could engage in a bit of
mischief overnight by moving a gene onto another chro-
mosome to the great surprise the next day of the editors
of that chromosome. In retrospect, positioning genes on
chromosomes appears to be a rather simple endeavor, espe-
cially now in view of the task of defining all of the variation
in thatmap. Although themappingmeetings as such came
to a natural end and genomemeetings took their place, the
map is surely yet to be finished, and a lot of fun remains to
be had. But, what was this all about? It was about the com-
ing together of a community and about our communica-
tion and sharing of the science of our discipline, whether
in the afternoon of a session in Bar Harbor on karyotyping
or in chromosome committees of the mapping meetings
held around the globe.
Part 2: Understanding the Variation
An undeniable challenge faces us now as we strive to
analyze immense data sets, extract useful information,
and annotate DNA variants. We often struggle to provide
an interpretation and find ourselves building the plane as
we are flying it. But, in truth, this is not a new road for
us to travel. As a human cytogeneticist for the past three
decades, I have been in the position of providing informa-
tion of uncertain clinical significance and of an incidental
nature to couples after prenatal analyses. One such coun-
seling session remains etched in my memory. I met with
a couple who had amniocentesis for advanced maternal
age of a treasured IVF twin pregnancy. The twins were
op-sexed, and the male co-twin harbored a supernumerary
inverted duplicated 15. This was a well-recognized chro-
mosome abnormality, but in those days before any molec-
ular analysis of this chromosomal aberration for clinical
interpretation was available, the phenotype ranged from
normal to abnormal. I telephoned Tim Donlon, one of
my cytogeneticist colleagues who had a research interest
in this chromosomal aberration, so that I would be current
on the latest information. We discussed the importance of
providing a balanced presentation of the scientific infor-
mation and of supporting the couple in whatever decision
they would make. We also spoke about the importance
of conveying the potential severity of the disorder so that
the counseling session might not be revisited in the future
with a perception that I had not portrayed ‘‘how unfortu-
nate’’ the outcome might be. I struggled with this thought
and then worried after the session whether I had been too
negative about the outcome from a self-defensive position.
Later, I received a thank-you note from the couple, who
informedme that they had decided to put all of the genetic
information aside and to enjoy the remainder of the
pregnancy. As could be reasonably expected, the baby
was well at delivery, and I sincerely hope that remained
to be the course of development.
There are several lessons from this case. First, as those
of us who have the privilege to serve the public know so
well, our patients recurrently teach us many poignant
lessons of life, and we cannot anticipate the view they, 2015
will have of the information we impart to them. Although
we are conscious of the reality that we do not walk in their
shoes, we are constantly reminded of that fact. Second,
and with relevance to the situation we find ourselves in
today in interpreting genetic variants and in dealing with
incidental findings, we have had a long history of deliv-
ering information that is of uncertain clinical significance
and that is of an incidental nature. I believe we are pre-
pared well for our position in this diagnostic space, and
we will continue compassionately to strive to provide
state-of-the-art knowledge to those who seek our assis-
tance. But, it is our responsibility to improve that knowl-
edge at the greatest possible speed. This will be a legacy
of our times. How will we go about this task?
Part 3: Treasuring Your Exceptions
Let’s return to the work of mapping (and annotating) the
human genome. We are still in that business, and there
is ample discovery yet to be made. And, we are skilled arti-
sans at that task and have tools that allow us to decipher
the underlying genetic etiology of the individual undiag-
nosed patient. From my earliest days as a human genetics
graduate student, I became familiar with the words of
William Bateson from his lecture The Method and Scope of
Genetics, delivered in 1908: ‘‘If I may throw out a word
of counsel to beginners, it is: Treasure your exceptions!’’
Individuals with chromosomal rearrangements, represent-
ing possibly n-of-1 experiments, have tremendous poten-
tial to tell us about the workings of our genome, as do
patients with undiagnosed diseases.
Over the past decade, my collaborators and I in the
Developmental Genome Anatomy Project (DGAP) have
exploited the biological resource of apparently balanced
chromosomal rearrangements in individuals with clinical
findings to discover genes involved in human develop-
ment. The endeavor beganwith fluorescence in situhybrid-
ization mapping of breakpoints, followed by Southern
blotting, cloning of rearranged DNA restriction fragments,
and Sanger sequencing. The development of next-genera-
tion sequencing changed all of that, as it has also done for
discovery of Mendelian disease. Now we can rapidly iden-
tify genes disrupted or dysregulated at chromosomal break-
points. From a decade now of work in this project, I can
assure you that in this approach, most of ‘‘the keys’’ (the
genes) are under the ‘‘the lamp post’’ (the chromosomal re-
arrangement). Each subject can illuminate a pathway yet to
be associated with a constellation of abnormal findings.
Spectacular advances in sequencing technologies have
made possible translation of nucleotide-level resolution
of chromosomal breakpoints into prenatal diagnostics.
In the last 2 years, we have provided informed genetic
counseling in six high-risk prenatal cases with de novo
apparently balanced rearrangements—consistent with
their normal array comparative genomic hybridization
(aCGH) findings—whereas two decades ago, Dorothy
Warburton’s cytogenetic studies of a series of newborns
with such rearrangements led to estimates of risk of anThe Ameuntoward outcome of 6.1% for a translocation and 9.4%
for an inversion.3 Two additional cases are underway.
The second case in our series was a 41-year-old female
whose fetus, at a gestational age of 16 weeks, had normal
first-trimester screening and a de novo paracentric inver-
sion of chromosome 8. Sequencing analysis revealed
disruption of KHDRBS3, encoding an RNA binding protein
involved in the regulation of RNA splicing. It gives me
great pleasure to report that this male child is now
23 months old, and all developmental milestones are
within normal limits, largely as a result of the advance-
ments in technologies we have available to us at this
time in our lives. Eighteen months after delivery, the
mom and her son, Julian, made a video for us, and the
mom stated, ‘‘If we were not here, if we were in some other
place, most likely Julian would not be born.’’
The days of turning away from investigating a single
rearrangement in a leukemia and requiring it to be consis-
tent in a series of patients before it would be worthy of
investigation are historical. So, I say, especially to my cyto-
geneticist colleagues in the audience, let’s capture all of
these exceptions that we have among our patients and
make this invaluable contribution to rapidly annotate
the genome. At this time in our lives, this is our obligation
to the next generations. Etched on the wall in my home
institution—Brigham and Women’s Hospital—above an
exhibit that housed the Nobel Prize awarded to Joseph
Murray for leading the team completing the first ever
human organ transplant were his words: ‘‘Service to society
is the rent we pay for living on this planet.’’ My fellow
geneticists, I think the time is now that our rent is due.
Part 4: Sharing Data
I’ll share with you one current example from DGAP
because it brings into focus the value and complexity of
communicating research results to participants and gives
us pause to think about how the growing number of
research results from genomic studies can be delivered in
a responsible, timely, and cost-efficient way. It is certainly
timely to think about data sharing given that the NIH
has recently issued the Genomic Data Sharing (GDS)
Policy.4 Sharing of large-scale human and non-human
genomic research data facilitates translation of research
findings into understanding that can lead to improve-
ments in human health. As a member of the Federation
of American Societies for Experimental Biology (FASEB),
comprising 27 scientific societies, ASHG has an important
role in shaping science policy. We are pleased to have had
an opportunity to provide comments and participate as
a signatory on a response to the draft GDS Policy. Although
the FASEB response commended the NIH for their leader-
ship, concerns were expressed about the increase in
administrative burden for investigators and institutions
(certainly a sign of our times) and a potential decrease in
human subject participation in clinical genomics research.
Within the next month, ASHG will participate in
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andOversight Framework for Laboratory Developed Tests,5
which no doubt is of great interest to many members of
our society. Other regulatory issues, including new individ-
ual data-access rights created by changes to federal privacy
and laboratory regulations, raise troubling questions for
genomic testing. Furthermore, the FDA has reached out
within the past year to researchers to assess whether inves-
tigational-device exemptions are required on the basis of
the level of risk to participants.
Recently, I provided the research results from our studies
of a subject (known as DGAP179) to a clinical geneticist for
her to explain to themom. Themomhad sent me an email
in May of this year to ask whether there were any results
available on her son, who she had enrolled in DGAP in
2003 when he was a toddler. In a subsequent email, she
stated that when she had attempted simple online web
searches, nothing popped up when she entered ‘‘chromo-
somal translocation 2 and 13’’ except for several hits refer-
ring to a cancer. She had found hits for a well-known
consistent rearrangement in alveolar rhabdomyosarcoma.
She commented that they putter along from day to day
while enjoying her son’s charm and good nature, but
that this past year has been characterized by frequent
illness, and that she was overcome by a sense of urgency
to find any information that would be helpful to her and
to provide details that might be helpful to other families.
We replied to her that we were working on this case, that
there would be results to report to her in the future, and
that we would be happy to explain experiments that
were underway. This mom is a special-education teacher,
and her son had been in her classroom for all of his
elementary school days. He would soonmove on tomiddle
school, and she was struggling with the thought of no
longer spending her entire day with him. Her son is non-
verbal and non-ambulatory but extremely social, and she
stated, ‘‘Everyone who meets him loves him.’’ Her emails
were filled with a mother’s love and pride. In July, she
wrote back to report that she had become Facebook friends
with a mom whose son has Pitt Hopkins syndrome and
that that mom had asked her whether she’d ever heard
of Mowat-Wilson Syndrome, which she had not. She
looked it up and stated that it could have been written
about her son! Also, the images looked like they could be
pictures of her son’s long, lost siblings—and some of
them could have been of him! She stated, ‘‘I really think
this is us! Sorry for all of the exclamation marks—it’s
kind of where I am right now ;-). I put in a call to the
genetics clinic of our children’s hospital today and will
anxiously await a reply. Though I’m scared it might be
months before they can see us.’’
As the DGAP research evolved over the first decade of
this century, we began to screen each de novo rearrange-
ment with aCGH to uncover potentially any other
genomic aberration that might have a role in the subject’s
phenotype beyond the apparently balanced disruption or
dysregulation of a gene at the breakpoints of the rearrange-
ment. We began our studies of DGAP179 in 2008 and350 The American Journal of Human Genetics 96, 347–351, March 5performed aCGH in our research laboratory, where we de-
tected two deletions believed to be pathogenic. A 1.7-Mb
deletion on the long arm of chromosome 2 included
ZEB2, a gene reported to be mutated in Mowat-Wilson
syndrome, consistent with various clinical findings at
enrollment of DGAP179. In addition, some clinical find-
ings were atypical but perhaps not inconsistent with
Mowat-Wilson syndrome. However, a 900-kb deletion on
chromosome 11 also disrupted CNTN5. Although we had
made an interpretation of the phenotype to be consistent
with the deletion of ZEB2, we believed we needed to
complete the sequencing of the translocation distant
from the deletion before the case could be reported, and
that only happened this year. Interestingly, the transloca-
tion between chromosomes 2 and 13 interrupts a tran-
script of the large intergenic noncoding RNA LINC00333
and a non-genic region on the short arm of chromosome
2. So, it’s a complicated ‘‘n-of-1 story’’ with two mega-
base-sized deletions and a translocation that disrupts a
non-coding RNA. Explaining all aspects of the subject’s
phenotype with the genomic findings is not easy—
certainly not simple to pass by any journal editors. That’s
my ‘‘excuse’’ for not communicating the results in a
more timely fashion, but in doing so, it has been at the
cost of depriving a loving mom a diagnosis, even if it is
in this case an incomplete explanation of the clinical find-
ings. I recall often the words of Di Donnai, who spoke on a
panel at an ASHG meeting a couple of years ago: ‘‘Never
underestimate the therapeutic importance of a diagnosis,
even when there is nothing that can be done.’’ But some-
thing could have been done in this case—the mom could
have received support from other families with children
with Mowat-Wilson syndrome, and I am sure that she
would have benefitted from such friendships. I think
differently now about the value of research results for
patients from this recent experience. In addition, although
the mom discovered the diagnosis of Mowat-Wilson
syndrome herself, and then her son was seen by a clinical
geneticist who agreed with her diagnosis, reporting
the research finding of a deletion of ZEB2 redirected the
confirmatory test by a CLIA-accredited laboratory to
aCGH rather than sequence analysis of ZEB2—another
valuable contribution from communicating the research
result.
I imagine that many of you are familiar with the story of
Matthew Might and Cristina Casanova. Titled ‘‘One of a
Kind,’’6 it was written this past summer by Seth Mnookin
in The New Yorker and concerns a newly diagnosed congen-
ital disorder of deglycosylation involving N-glycanase 1.
There are many lessons therein, including yet another
success of exome sequencing, but this report also illumi-
nates issues akin to those in the DGAP179 tale. On a posi-
tive shared note, it reports how the use of social media can
help families affected by rare diseases find other families
(such as Facebook friends in DGAP179). In this article, a
mom who attended a Rare Disease Symposium meeting
stated, ‘‘It feels like we’ve come home, but to a home we, 2015
didn’t know we had.’’ In another aspect, it brings up the
issue of sharing data with subjects—and I quote, ‘‘As a mat-
ter of protocol, researchers typically avoid sharing test re-
sults with subjects until the research is published’’—and
sharing data with competitors out of concerns about
publication. Both are data-sharing issues of disservice to
those who need our assistance. Now, I’ll make a note added
in proof of this address from reading a Commentary7 in
the October 2014 issue of Genetics in Medicine while on
my flight from Boston to San Diego on Thursday. It is
co-authored by Matthew Might and Matt Wilsey, both fa-
thers of children with this same deglycosylation disorder.
In the last paragraph, these dads speak to us: ‘‘When you
have a bad day in the clinic or the laboratory, please
remember that there are patients and parents out there
who you do not know and who are dreaming of finding
you, supporting you, and counting on you.’’ Matthew
and Matt, thank you both so much for these uplifting
words. I assure you that assembled in this hall is a commu-
nity of individuals committed deeply and on a daily basis
to the challenges your families’ stories have defined so
well. You can count on us.
We must share the information we learn. Various efforts
are underway and are addressing this challenge. Earlier
today, the Global Alliance for Genomics and Health held
its second plenary meeting here in San Diego. The Global
Alliance, founded just last year, is an international coali-
tion working to enable the sharing of genomic and clinical
data. Its over 220 partners are dedicated to improving
human health by maximizing the potential of genomic
medicine. ASHG is proud to be a founding partner
of the Global Alliance, and many of our members are
active participants in its working groups. We believe that
this international partnership will be highly effective
in unlocking potential advancements in human health,
and we’re excited to join with hundreds of diverse leaders
in healthcare and biomedical research, patient and disease
advocacy, and life science and information technology. By
sharing data, we can all do our part to hasten knowledge
growth and improve medical outcomes.
Part 5: Ending with a Surprise
I want to thank all of you, for as members of ASHG, you
made it possible for me to carry two of the best business
cards that I could ever have dreamed to have in my
pocket—as your 2014 president and as the editor of The
American Journal of Human Genetics. I also want to mention
three wonderful mentors who were instrumental in the
passages in my career from graduate school to postdoc to
faculty. These three individuals are an all-star group, andThe AmeI am ever grateful to the guidance of Walter Nance, Philip
Leder, and Ramzi Cotran. Then there are those with whom
I trained and those whom I trained; you all know who you
are, and I hope you know how much I appreciate your
friendship and support over these many years. I’d also
like to mention Katy Phelan, who was my roommate in
graduate school and who has roomed with me at countless
ASHG meetings since the first meeting we attended in
Minneapolis in 1979. Lastly, I want to thank my family:
my husband, Bill, my son, Russell, and my daughter,
Emily, shown here on a trip to the Galapagos Islands,
where once more in life they were accommodating
in some way their family geneticist—this time on a
pilgrimage she had to make.
Now, it’s really that time to wrap up one more presiden-
tial address. Let’s think about the exciting meeting
ahead of us this next week and the special colleagues
with whom we will have ‘‘the time of our lives’’ and share
a ‘‘common glory.’’ My surprise ending is to close with a
clip from The Common Glory. Let’s communicate, collabo-
rate, and share a common glory!References
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